Tirzepatide Before and After: What Trial Data Actually Shows

You have seen tirzepatide before and after pictures online. Influencers showing dramatic transformations. Reddit threads with side-by-side photos. Instagram accounts dedicated to weight loss progress. So you searched “tirzepatide before and after” to see what’s realistic and what to actually expect.

This page does not include those photos. Here is why, and what you will find instead.

Why this page has no before and after photos

The photos you see on social media are not representative. This is not pessimism. It is accurate expectation-setting based on how social media works and how the FTC treats weight loss claims.

Social media amplifies outliers. The person who loses 80 pounds posts about it. The person who loses 18 pounds, improves their energy, and feels like their body is finally listening again, does not. The feed is filled with the top end of outcomes. These may be real results, but they are not typical results.

The FTC’s Endorsement Guides say that when an ad shows a consumer’s results, people are likely to read it as what most users will generally achieve. An advertiser that cannot back that up has to clearly disclose the results people can generally expect^[4]. The FTC’s 2024 rule on consumer reviews and testimonials also bans fake testimonials, including ones that misrepresent a person’s experience^[5]. Showing you the 20 most dramatic before and afters from social media and calling them “results” would be misleading. Most people taking tirzepatide will not look like those photos.

Instead, here is what the clinical data shows. It comes from controlled trials with large groups of participants, not selected social media posts. This is what “before and after” means when you remove the selection bias.

What the SURMOUNT trials found (the real data)

In 2022, researchers published SURMOUNT-1, a large randomized controlled trial of tirzepatide in 2,539 adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with at least one weight-related condition. People with diabetes were excluded^[1]. This is your reference point.

The trial ran for 72 weeks (just under 17 months). Participants received weekly tirzepatide at 5mg, 10mg, or 15mg, or a placebo. Everyone, including the placebo group, received instruction on a reduced-calorie diet, physical activity counseling, and behavior counseling^[3]. The tirzepatide studied was the manufacturer’s FDA-approved product, which Eli Lilly and Company sells as Zepbound for weight management and Mounjaro for type 2 diabetes^[3][6]. Here is what happened.

The mean results (what “average” actually looks like)

At the highest dose (15mg weekly), participants had a mean body weight reduction of 20.9%^[1]. The placebo group, with the same diet and activity counseling, lost 3.1%.

For context, participants started at an average of 104.8 kg (about 231 pounds)^[1]. A 20.9% reduction from that starting point is roughly 48 pounds. That is arithmetic on a group average, not a prediction for any individual.

These are averages. Some people in the trial lost more. Some lost less. Results vary.

At the 5mg dose, the mean reduction was 15.0%^[1]. At the 10mg dose, it was 19.5%^[1].

Who achieved what outcome

Here is the part that matters for your expectations: 57% of participants on the 15mg dose lost at least 20% of their body weight, compared with 3% on placebo^[1]. That means about 43% did not reach that threshold, even at the highest dose.

This is not a failure on their part. Responses to any medication vary. Some of that variation is genetics. Some is diet and activity. Some is things researchers do not fully understand yet.

You need to know this before you start. Someone else taking tirzepatide may have very different results from yours. This is not about willpower or effort. It is biology.

What about tirzepatide versus semaglutide?

SURMOUNT-5 is the only head-to-head trial so far. It randomly assigned 751 adults with obesity but without type 2 diabetes to the highest dose they tolerated of tirzepatide (10mg or 15mg) or semaglutide (1.7mg or 2.4mg) for 72 weeks. Average weight loss was 20.2% with tirzepatide and 13.7% with semaglutide^[7]. The trial was open-label and funded by Eli Lilly. Those are averages for the brand-name medicines as studied, not a prediction for any individual, and some people do better on semaglutide. Our semaglutide vs tirzepatide comparison covers both medications’ side effects and label warnings.

What the timeline actually looks like

The before and after photos online often span many months of treatment. Most people posting them did not see dramatic results after 3 months. But if you search “tirzepatide results 3 months,” the expectation-setting is often poor.

Here is what the FDA-approved label and the SURMOUNT-1 trial design tell you about timing. Individual experience varies widely.

The SURMOUNT-1 averages describe participants at the full 72 weeks. They are not what people saw at month 3 or month 6.

Why social media results are not your baseline

Four factors explain why the before and after photos online do not represent what most people experience.

1. Selection bias (only wins get posted)

The person who lost 12 pounds and feels better does not post about it. The person who lost 68 pounds in a year posts about it extensively. Your social media feed is a curated collection of the top end of outcomes.

2. Baseline differences you cannot see

The people posting dramatic results may have started with a significantly higher BMI than you. Someone who starts at 350 pounds and loses 70 pounds looks more dramatic than someone who starts at 220 pounds and loses 44 pounds. Same percentage, different visual impact. You cannot see the starting point from the final photo.

3. Timing and patience

The influencers posting the most dramatic before and afters have often been taking tirzepatide for a year or more. A post labeled “3-month results” may come from someone who started at a high weight or responded unusually well. You usually cannot tell their dose, their timeline, or what else changed.

4. Compounding factors beyond medication

People who post results are often also:

• Tracking food intake (not restricting, but aware)
• Exercising regularly (walking, strength training, cardio)
• Sleeping better
• Managing stress
• Taking the medication exactly as prescribed

The medication is one lever. The other levers matter.

What actually affects your results

You will end up somewhere on the spectrum from “modest weight loss with improved energy” to “substantial weight loss near the trial average” or beyond. Where you land depends on factors within and outside your control.

You can influence these

Protein intake. The medication makes it easier to eat less, and adequate protein helps support body composition while you lose weight. Ask the prescriber or a dietitian what target makes sense for you.

Resistance exercise. Walking is great. Adding resistance training (weights, bodyweight, bands) supports muscle and strength while you lose weight.

Consistent dosing. Tirzepatide is taken once a week. Missing doses or stretching the schedule can keep you at lower levels longer. The label says a missed dose can be taken within 4 days; after that, skip it and take the next dose on the usual day^[3].

Staying with treatment. Some people stop because of side effects that do not settle. Some stop because they expected faster results. In SURMOUNT-1, the average results were measured after 72 weeks of treatment, and higher assigned doses produced larger average weight loss^[1].

You cannot easily change these

Your metabolic starting point. People differ in how they respond to GLP-1 medications. Genetics, insulin sensitivity, and other factors play a role. This is not your fault.

Concurrent medications. Some medications can make weight loss harder, and some promote weight gain. If you take medications for other conditions, raise that with the prescriber.

Hormonal factors. Perimenopause, thyroid status, and other hormonal patterns can influence weight. They are worth raising with the prescriber.

Underlying conditions. Type 2 diabetes, PCOS, and other metabolic conditions can affect weight loss. In a separate 72-week trial of adults with type 2 diabetes, average weight loss was 12.8% on 10mg and 14.7% on 15mg, compared with 3.2% on placebo^[3]. That was a different trial with different participants, so it is not a direct comparison with SURMOUNT-1.

This list is not to discourage you. It is to help you understand that if your results differ from someone else’s, it is not a character flaw or sign you are “doing it wrong.” It is biology.

Understanding trial data vs. your outcome

The SURMOUNT-1 results (20.9% mean reduction at 72 weeks on 15mg) are the most honest baseline you have. But they are an average. On 15mg, 91% of participants lost at least 5% of their body weight, and 57% lost at least 20%^[1]. Some lost more than the average and some lost much less.

Important context: every participant received diet, activity, and behavior counseling^[3]. The FDA-approved label pairs tirzepatide with a reduced-calorie diet and increased physical activity^[3]. The trial results reflect medication plus that support.

Also important: the trial data is for the FDA-approved brand-name tirzepatide studied under trial conditions. Compounded tirzepatide contains tirzepatide, but it is not FDA-approved, it was not the product studied in these trials, and it may differ in formulation, purity, and potency. The FDA does not review compounded medications for safety, effectiveness, or quality^[8], so you cannot assume a compounded product produces the trial results. Our page on whether compounded tirzepatide works covers this in detail.

Practical expectations for your first year

The trial gives you a realistic frame, not a personal forecast:

• The first months: the dose is still rising, and much of the early period is about tolerating the medication. Appetite changes often come before visible change.
• Mid-year: most people in SURMOUNT-1 had reached their assigned dose by week 20. Weight loss generally builds gradually from there.
• At 72 weeks (about 17 months): this is where the SURMOUNT-1 averages (15.0% to 20.9% by dose, versus 3.1% on placebo) were measured^[1].

These are trial facts, not a prediction. Where you land depends on the factors listed above. Results vary.

One more thing: the people online showing results at 3 months are often the top responders. Do not anchor your expectations to their timeline. The trial ran 72 weeks.

Dose and response: how much does the dose matter?

SURMOUNT-1 assigned participants to fixed doses, which shows how much dose mattered on average^[1]:

• 5mg weekly: 15.0% mean weight loss
• 10mg weekly: 19.5% mean weight loss
• 15mg weekly: 20.9% mean weight loss
• Placebo: 3.1% mean weight loss

The difference between the 5mg and 15mg averages is 5.9 percentage points.

There is another layer: higher doses can bring more side effects. In SURMOUNT-1, side effects led 4.3%, 7.1%, and 6.2% of participants on 5mg, 10mg, and 15mg to stop treatment, compared with 2.6% on placebo^[1]. The label says to consider response and tolerability when choosing a maintenance dose, and to consider a lower dose if a person does not tolerate one^[3].

The practical takeaway: the dose that works for you is the one you and the prescriber choose based on how you respond and how you feel. A lower maintenance dose still produced meaningful average weight loss in the trial, in a different range.

The prescriber you choose decides this with you. If side effects are hard to tolerate, tell them; you do not have to push through on your own.

Understanding the distribution: why results vary so much

The SURMOUNT-1 trial reported a mean reduction of 20.9% on 15mg. An average hides how widely outcomes spread. Here is the share of participants who reached each threshold at 72 weeks, from the trial results as reported on the Zepbound label (SURMOUNT-1 is “Study 1” there)^[3]:

This distribution is important. Roughly 1 in 10 participants on 15mg did not reach 5%, and more than 4 in 10 did not reach 20%.

Factors associated with response, based on the trial and the label:

• Dose: participants on 10mg or 15mg lost more on average than those on 5mg^[1]
• Type 2 diabetes: in a separate trial of adults with type 2 diabetes, average weight loss was lower (12.8% on 10mg, 14.7% on 15mg)^[3]
• Staying on treatment: in SURMOUNT-4, people who stopped tirzepatide regained much of the weight they had lost^[2]
• Consistency: missed or irregular doses can keep you at lower levels

The label also notes that weight reduction was seen regardless of age, sex, race, ethnicity, baseline BMI, and glycemic status^[3]. None of these factors guarantees an outcome. They point toward what affects response.

If your results are at the high end, you may look like the Instagram posts. If they are closer to the middle, you may look noticeably different and feel better without a “transformation” photo. If you lose less than you hoped, the prescriber can review whether a dose change, a different medication, or other factors are worth looking at.

Knowing this distribution helps you understand where you might fit. It is not about effort. It is about biological response. And it is why the before and afters online, showing the top end of outcomes, are misleading as a baseline expectation.

Risks to weigh alongside the results

Tirzepatide has risks as well as benefits. On the Zepbound label, the most common side effects include nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, injection site reactions, fatigue, hypersensitivity reactions, burping, hair loss, and gastroesophageal reflux. The label carries a boxed warning about thyroid C-cell tumors seen in rats, and tirzepatide should not be used by people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2, or by anyone with a known serious allergy to it. Label warnings also cover severe stomach and bowel side effects, kidney injury from dehydration, gallbladder disease, pancreatitis, serious allergic reactions, and low blood sugar when used with insulin or a sulfonylurea. Because tirzepatide slows stomach emptying, the label advises people taking birth control pills to switch to a non-oral method, or add a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase. It may cause harm in pregnancy^[3]. Label information describes the brand-name product.

What happens if you stop

In the SURMOUNT-4 trial, adults who had lost an average of 20.9% over a 36-week lead-in on tirzepatide were randomly assigned to keep taking it or switch to placebo. Over the next 52 weeks, the placebo group regained an average of 14.0% of body weight, while the group that continued lost a further 5.5%^[2].

This matters for how you think about the medication long-term. It is not a one-time fix. It is a medical tool for as long as you use it. Any plan to reduce or stop it should be made with the prescriber, along with the habits that will support you either way.

Program options to review

Transformation Health does not prescribe, sell, or compound tirzepatide. If you are comparing programs that offer it, check:

• Which product they prescribe. Brand-name tirzepatide (Zepbound or Mounjaro) is FDA-approved. Compounded tirzepatide is not FDA-approved and is not the same product.
• Who prescribes. A licensed provider (a physician, nurse practitioner, or physician assistant) should review your health history and decide whether a prescription is appropriate.
• How dosing is handled. Ask how the program sets the starting dose and escalation schedule, and how you reach the prescriber if side effects are hard to manage.
• Monitoring. Ask whether labs or follow-up visits are part of the program and who orders and reviews them.
• Total cost. Prices vary by program and dose. Compare the total cost: medication, dose increases, visits, labs, shipping, membership fees, and cancellation terms.

Transformation Health does not accept payment from providers. How we make money.

Next steps

If you are considering tirzepatide, start with an honest assessment:

• Are you looking for a 3-month transformation, or are you willing to commit to many months of treatment?
• Are you ready to make nutrition and activity changes alongside medication, or are you hoping the medication alone will do the work?
• Do you fit the label’s group? Zepbound is indicated for adults with obesity, or with overweight and at least one weight-related condition, alongside diet and activity^[3]. A licensed provider decides whether it is appropriate for you.
• Can you manage the cost and the ongoing commitment?

The before and after you create will be your own. It will not look like the influencer’s. It will reflect your biology, consistent medical oversight from the provider you choose, and the habits you build.

Citations

[1] Jastreboff AM, Aronne LJ, Ahmad NN, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” N Engl J Med. 2022;387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/

[2] Aronne LJ, Sattar N, Horn DB, et al. “Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.” JAMA. 2024;331(1):38-48. https://pubmed.ncbi.nlm.nih.gov/38078870/

[3] U.S. Food and Drug Administration. ZEPBOUND (tirzepatide) injection, prescribing information. Revised 08/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf

[4] Federal Trade Commission. Guides Concerning the Use of Endorsements and Testimonials in Advertising, 16 CFR 255.2(b). https://www.ecfr.gov/current/title-16/chapter-I/subchapter-B/part-255 (Accessed 2026-10-16.)

[5] Federal Trade Commission. Rule on the Use of Consumer Reviews and Testimonials, 16 CFR 465.2. 89 FR 68077, August 22, 2024. https://www.ecfr.gov/current/title-16/chapter-I/subchapter-D/part-465 (Accessed 2026-10-16.)

[6] U.S. Food and Drug Administration. MOUNJARO (tirzepatide) injection, prescribing information. Revised 04/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866Orig1s052lbl.pdf

[7] Aronne LJ, Horn DB, le Roux CW, et al. “Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.” N Engl J Med. 2025;393(1):26-36. https://pubmed.ncbi.nlm.nih.gov/40353578/

[8] U.S. Food and Drug Administration. “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.” Content current as of 10/01/2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss (Accessed 2026-10-16.)